大脑缺血中的脂质代谢:从发病到治疗
Xinrong Wang1, Rongjia Liu1, Zhong Chen1,2
1Department of Pharmacology and Department of Pharmacy of The Second Affiliated Hospital, Key Laboratory of Medical Neurobiology of The Ministry of Health of China, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Current neuropharmacology
|July 25, 2025
概括
脂质代谢显著影响大脑缺血,驱动有害的神经炎症和保护性修复机制. 针对这些途径为中风治疗提供了有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 大脑缺血是全球死亡和残疾的主要原因.
- 脂质代谢失调是脑缺血复杂病理的核心.
- 了解脂质在神经炎症和神经保护中的作用至关重要.
研究的目的:
- 审查脂质代谢在脑缺血病原发生中的关键作用.
- 探索神经炎症中的脂质介质 (例如,AA代谢物) 和神经保护 (例如,SPM).
- 检查针对脑缺血的脂质通路的治疗潜力.
主要方法:
- 关于脑缺血中脂质代谢的文献综述.
- 对阿拉基酸 (AA) 代谢物通路 (COX,LOX) 的分析.
- 专业化解决方案调解员 (SPMs) 及其职能的审查.
- 检查PPAR和脂体信号传导作用.
主要成果:
- AA代谢物 (前列腺素,LT) 促进神经炎症并加剧损伤.
- SPM (脂毒素,Resolvins,蛋白质) 解决炎症,并有助于组织修复.
- PPARs和sphingolipids调节氧化应激,线粒体功能和神经元的生存.
结论:
- 脂质代谢在脑缺血中起着双重作用,有助于损伤和修复.
- 针对特定的脂质通路,如SPM,对脑缺血症具有治疗前景.
- 这篇评论将基本的脂质科学与用于新型中风治疗的临床研究联系起来.
更多相关视频
相关概念视频
Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Atherosclerosis I: Introduction
87
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
87


